329 related articles for article (PubMed ID: 33169186)
21. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial.
Morita J; Tanaka M; Nomoto M; Matsuki S; Tsuru T; Matsuguma K; Shiramoto M
BioDrugs; 2016 Feb; 30(1):17-25. PubMed ID: 26691837
[TBL] [Abstract][Full Text] [Related]
23. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin
Zhu Y; Li C; Chen L; Liu H; Ou L; Li T; Wang X; Wang T; Tian J; Liang X; Hu Z; Zhan Y; Xiao S; Wang X; Li Y; He J; Zheng Q; Song H; Li X; Fang Y
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):383-392. PubMed ID: 38564097
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind, parallel-group, single-dose comparative pharmacokinetic study of DRL_TZ, a candidate biosimilar of trastuzumab, with Herceptin
Lickliter JD; Dadhania RN; Trivedi RK; Naveen Kumar SR; Reddy PK
Indian J Med Res; 2021 Mar; 154(3):509-519. PubMed ID: 35142643
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
26. A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.
Pivot X; Deslypere JP; Park LS; Kim MJ; Lee W; Lee J
Clin Ther; 2018 Mar; 40(3):396-405.e4. PubMed ID: 29502805
[TBL] [Abstract][Full Text] [Related]
27. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
Markus R; Chow V; Pan Z; Hanes V
Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
[TBL] [Abstract][Full Text] [Related]
29. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
[TBL] [Abstract][Full Text] [Related]
30. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
[TBL] [Abstract][Full Text] [Related]
32. A randomized, single-blind, single-dose, parallel-group study in healthy subjects to demonstrate the pharmacokinetic equivalence of trastuzumab and its biosimilar.
Wang Y; Liu Z; Deng Q; Su Z; Xue J; Zhao Y; Yang H
Expert Opin Drug Metab Toxicol; 2023; 19(11):849-855. PubMed ID: 37526387
[TBL] [Abstract][Full Text] [Related]
33. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers.
Shin D; Lee Y; Kim H; Körnicke T; Fuhr R
J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
36. Comparison of SB17 and reference ustekinumab in healthy adults: A randomized, double-blind, single-dose, phase I study.
Jeong H; Kang T; Lee J; Im S
Int J Clin Pharmacol Ther; 2024 May; 62(5):231-240. PubMed ID: 38174886
[TBL] [Abstract][Full Text] [Related]
37. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
[TBL] [Abstract][Full Text] [Related]
38. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
39. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
40. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
